In contrast, the TP53/KRAS comutation combination exhibited a stronger improvement in PD-L1 expression and enhanced tumor immunogenicity compared with the KRAS or TP53 single mutation [39], highlighting the importance of a model that would combine the different genes. This evidence concerns the gene TP53 and neoplasm.